Related Experiment Video
Updated: May 10, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
[Expert guidance and consensus for standardization of lipid profile testing report in China]
L Zhang1, Z Y Chen2, D Q Peng3
1Department of Cardiology, Peking University First Hospital, Beijing 100034, China.
Insights
Standardizing lipid profile testing reports in China is crucial for personalized dyslipidemia treatment. This aims to improve diagnosis, patient compliance, and cardiovascular disease (CVD) risk management.
Area of Science:
- Cardiology
- Clinical Pathology
- Public Health
Background:
- Current lipid profile reports in China lack risk stratification, hindering individualized treatment for dyslipidemia.
- Existing formats use general reference ranges unsuitable for diverse patient risk levels.
Purpose of the Study:
- To standardize lipid profile testing reports in China for precise dyslipidemia diagnosis and assessment.
- To improve treatment and long-term compliance rates for dyslipidemia patients.
- To guide clinical reform of lipid profile testing reports.
Main Methods:
- Multidisciplinary expert group convened to formulate standardization guidance.
- Development of "Expert guidance and consensus for standardization of lipid profile testing report in China" issued.
Main Results:
- Provides a framework for reforming and standardizing lipid profile testing reports.
- Aims to increase awareness and diagnosis of dyslipidemia among healthcare professionals and patients.
- Facilitates individualized risk assessment and precision treatment regimens.
Conclusions:
- Standardized reports will enhance lipid management systems and medical resource utilization.
- Expected to reduce cardiovascular disease (CVD) risk and associated healthcare costs.
- Promotes significant public health and economic benefits through improved dyslipidemia care.
Abstract:
Domestic and international guidelines focusing on ASCVD risk stratification and precision treatment of dyslipidemia emphasize the formulation of individualized LDL-C targets based on risk stratification. However, in current clinical practice in China, most lipid profile testing reports adopt a single presentation format, with the indicated reference ranges only applicable to the general healthy population, which fails to meet the needs of stratified treatment for patients with varying risk levels.To promote the precise diagnosis and assessment of dyslipidemia, and improve the treatment rate and long-term compliance rate of dyslipidemia, the Expert Group of Expert guidance and consensus for standardization of lipid profile testing report in China has organized multidisciplinary experts to formulate and issue Expert guidance and consensus for standardization of lipid profile testing report in China. This document provides guidance for the clinical reform of lipid profile testing reports. Through the reform and standardization of lipid profile testing reports, it aims to raise the awareness and attention of cardiologists, non-cardiovascular specialists, and patients with dyslipidemia, improve the awareness and diagnosis rates of dyslipidemia among different populations, and facilitate the implementation of individualized risk assessment and precision treatment regimens. It will also help establish a more scientific and efficient system for lipid management, enhance the efficiency of medical resource utilization, reduce the risk of CVD and the associated burden on medical insurance expenditures, and yield greater public health and economic benefits.
